RareCyte CyteFinder II CTCs and Rare Cell Detection Imaging Picking

Overview

Circulating Tumor Cells (CTC) in Clinical Research: CTC Enumeration

RareCyte enables practical deployment of circulating tumor cell (CTC) and rare cell-based liquid biopsy with instrumentation and consumables that provide an exquisitely sensitive, accurate, reproducible, and transparent workflow from blood collection to single cell isolation.

  • Unbiased, reproducible, highly sensitive, and specific rare cell detection
  • Scalable, high-capacity platform with workflow breakpoints, including slide banking, that enable multi-site execution
  • Deploy through our global contract research organization (CRO) network or in your own lab
  • Utilize cancer-specific panels or Developer panels for CTC biomarker analysis
  • Custom assay and companion diagnostics co-development through our Precision Biology Services

Publication: Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer

https://link.springer.com/article/10.1007/s10549-022-06585-5

 

High Sensitivity for Precise Single-Cell Analysis and Retrieval

  • Sensitivity: Platform tailored for ultra-rare cell collection, identification, and isolation
  • Specificity: Protein expression heterogeneity among rare target cells revealed with up to six channels, and image-based cell identification and selection ensures integrity of single cell data
  • Retrieval: Gentle single cell isolation from multiple sample preparation types that enable both DNA and RNA analysis

CTC surrounded by white blood cell

SK-BR-3 model CTC surrounded by white blood cells on AccuCyte® slide. CK / EpCAM (magenta) / nuclei (blue).

Immunofluorescence Imaging for Rare Cell Detection

Circulating Tumor Cell (CTC) Enumeration in Cancer Research

CTC enumeration was demonstrated to be prognostic of outcome nearly two decades ago3. Advances in CTC technology now allow interrogation of cancer phenotypes and likelihood they might be responsive to therapeutics.

  • Since CTCs contain intact whole cancer genomes, isolating viable CTCs detected during therapy facilitates study of mutational profiles of resistance
  • Identification, characterization and molecular analysis of CTCs will advance the capacity of liquid biopsy to meet the needs of twenty-first century medicine
  • Circulating tumor cell enumeration enables more effective prognostic testing and ctc count assesses earlier therapeutic responses of advanced disease
  • Testing for circulating tumor DNA (ctDNA) examines a patient’s blood to detect DNA fragments from cancer cells enabling the identification of minimal residual disease through testing.

CyteFinder® II Instruments are high-speed, whole slide imaging systems with options for multiplexed liquid biopsy and tissue spatial analysis. IF, H&E, and IHC modes for imaging blood smears, tissue sections, and cytology preparation including fine needle aspirates.

Integrated machine learning algorithm detects and rank orders candidate cells for user review. Tissue option for digital pathology on the CyteFinder II Instrument. CytePicker® Retrieval Module enables single cell or tissue micro-region retrieval from any location on the slide.

Case Study

Accurate CTC detection is critical in the recovery of useful, quantitative data from patient blood. A research article published in Frontiers in Oncology describes the AccuCyte process for CTC isolation and CyteFinder II’s immunofluorescence staining and imaging, together providing a reliable and accurate workflow at > 95% when compared to recovery rates using density or lysis-based processes.

CyteFinder workflow from blood to image data

 

Read more from this study ➝

Accurate isolation and detection of circulating tumor cells using enrichment-free multiparametric high resolution imaging
Yeo D, Kao S, Gupta R, et al.
University of Sydney, Sydney, Australia

CytePicker Retrieval Module: Single Cell Isolation with Pristine Sample Preservation

CytePicker Retrieval Module

Needle-based system used to isolate a single cell or tissue micro-region for molecular analysis.

  • Reliably retrieve a single cell or tissue micro-region and visually confirm deposit
  • Preserves sample integrity for molecular analyses
  • Autoloading needles
  • Available on CyteFinder® Instrument only

Pancreatic cancer tissue

Pancreatic cancer tissue micro-region retrieved with CytePicker Retrieval Module. CK (green) / Nuclei (blue)

WEBINAR: Analytical Validation of CTC Enumeration using the RareCyte Platform and Implementation in a Global Clinical Trial

Learn how the RareCyte platform for CTC analysis was validated in the Clinical Diagnostics Lab (CAP accredited CLIA Lab) at Eli Lilly and the platform added to a global clinical trial for further evaluation in collaboration with a CRO.

Speakers:

  • Jeff Fill MBA, MT(ASCP)
    Senior Director, Diagnostic and Experimental Pathology, Lilly Research Laboratories, Eli Lilly and Company
  • Arturo Ramirez PhD
    Director of Oncology, RareCyte Inc.

CTC Enumeration for metastatic breast cancer assay, castration-resistant prostrate cancer assay, and Developer Kit AR

View the Webinar

https://rarecyte.com/pdf/2019ACTCposter.pdf

https://rarecyte.com/pdf/PickSeq_Poster_SITC_2019.pdf

RareCyte CyteFinder II CTCs and Rare Cell Detection Imaging Picking

To get more information or a quote for this product

Please fill out our form ,and we’ll get in touch shortly